PMA P130013S043

Device
WATCHMAN™ and WATCHMAN FLX™ Left Atrial Appendage Closure Devices with Delivery Systems
Applicant
Boston Scientific Corp
Product code
NGV
Decision date
2022-09-02
Generic name
System, appendage closure, left atrial
Approval order statement
Approval for the addition of dual antiplatelet therapy (DAPT) as an alterative post-implant antithrombotic medication regimen.

Current openFDA PMA Record#

Device
WATCHMAN™ and WATCHMAN FLX™ Left Atrial Appendage Closure Devices with Delivery Systems
Applicant
Boston Scientific Corp
PMA number
P130013
Supplement
S043
Product code
NGV
Generic name
System, appendage closure, left atrial
Decision date
2022-09-02
Decision code
APPR
Date received
2021-03-31
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
Approval for the addition of dual antiplatelet therapy (DAPT) as an alterative post-implant antithrombotic medication regimen.